Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer

By Gijs Marlies   Penner Gregory   Blackler Garth B.   Impens Nathalie R.E.N.   Baatout Sarah   Luxen André   Aerts An M.  

Pharmaceuticals, Vol. 9, Iss. 2, 2016-05 ,pp. : 29-29

MDPI

Access to resources Recommend Favorite

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

By Lammers Philip   Criscitiello Carmen   Curigliano Giuseppe   Jacobs Ira  

Pharmaceuticals, Vol. 7, Iss. 9, 2014-09 ,pp. : 943-953

MDPI

Access to resources Recommend Favorite

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

By Serwotka-Suszczak Anna M.   Sochaj-Gregorczyk Alicja M.   Pieczykolan Jerzy   Krowarsch Daniel   Jelen Filip   Otlewski Jacek  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 401-401

MDPI

Access to resources Recommend Favorite

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells

By Yamaguchi Haruka   Hayama Kazuhide   Sasagawa Ichiro   Okada Yasuo   Kawase Tomoyuki   Tsubokawa Norio   Tsuchimochi Makoto  

International Journal of Molecular Sciences, Vol. 19, Iss. 3, 2018-03 ,pp. : 908-908

MDPI

Access to resources Recommend Favorite

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

By Caggiari Laura   Miolo Gianmaria   Buonadonna Angela   Basile Debora   Santeufemia Davide A.   Cossu Antonio   Palmieri Giuseppe   De Zorzi Mariangela   Fornasarig Mara   Alessandrini Lara   Canzonieri Vincenzo   Lo Re Giovanni   Puglisi Fabio   Steffan Agostino   Cannizzaro Renato   De Re Valli  

International Journal of Molecular Sciences, Vol. 19, Iss. 1, 2017-12 ,pp. : 47-47

MDPI

Access to resources Recommend Favorite